Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female study participants with sickle cell disease~2. Participants have had at least 1 episode of vaso-occlusive crisis (VOC) in the past 12 months.~3. Age 12 to 65 years~4. Hemoglobin (Hb) ≥5.5 and ≤10.5 g/dL during screening~5. For participants taking hydroxyurea (HU), the dose of HU (mg/kg) must be stable for at least 3 months prior to signing the ICF.~Exclusion Criteria:~1. More than 10 VOCs within the past 12 months that required a hospital, emergency room or clinic visit~2. Patients who are receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) or have received a RBC transfusion for any reason within 60 days of signing the ICF~3. Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days of signing the ICF (i.e., a vaso-occlusive event cannot be within 14 days prior to signing the ICF)~4. Hepatic dysfunction characterized by alanine aminotransferase (ALT) \>4 × upper limit of normal~5. Severe renal dysfunction (estimated glomerular filtration rate at the Screening visit; calculated by the central laboratory) \<30 mL/min/1.73 m\^2 or on chronic dialysis

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dose 1 (Type: ACTIVE_COMPARATOR): voxelotor
- Dose 2 (Type: ACTIVE_COMPARATOR): voxelotor
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).